<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0024796" disease_type="Disease or Syndrome" abbrv="MFS|MFS1">Marfan syndrome</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MFS</z:e>) and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MFS</z:e>-related diseases are inherited <z:e sem="disease" ids="C0009782" disease_type="Disease or Syndrome" abbrv="">connective tissue disorders</z:e> involving several organ systems </plain></SENT>
<SENT sid="1" pm="."><plain>The diagnosis of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MFS</z:e> is difficult as the many symptoms overlap with those of other systemic <z:e sem="disease" ids="C0009782" disease_type="Disease or Syndrome" abbrv="">connective tissue diseases</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>The phenotype is progressive </plain></SENT>
<SENT sid="3" pm="."><plain>Effective surgical therapy and standardized follow-up programs have led to an improved lifespan for the affected individuals </plain></SENT>
<SENT sid="4" pm="."><plain>Selective <z:chebi fb="0" ids="2719,48432">angiotensin II</z:chebi>, type 1 (AT1) blockers may improve several manifestations of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MFS</z:e>, but the outcome of clinical trials is presently unknown </plain></SENT>
<SENT sid="5" pm="."><plain>This review describes the importance of a coordinated strategy for diagnosis, treatment and follow-up </plain></SENT>
</text></document>